Su et al. (2011) coupled BTZ with a polymer carrier containing catechol through a reversible dynamic covalent borate ester bond and then synthesized a new type of cell-targeted and pH-sensitive polymer carrier by modifying biotin-targeted ligands that are selectively ingested by cancer cells through the mechanism mediated by cell surface receptors, thus delivering the anticancer drug BTZ to cancer cells. The gene discussed is CD177; the disease is cancer.